体积微采样用于门诊肾移植受者免疫抑制剂与肾功能同步远程监测
本研究开发并验证了可同时定量干血斑(DBS)与体积吸收微样本(VAMS)中他克莫司、霉酚酸(MPA)、肌酐和碘海醇的液相色谱-串联质谱法,并与25例肾移植受者的静脉参考样本直接比较。DBS对他克莫司谷浓度和AUC、肌酐基GFR趋势监测方法一致性优良,MPA AUC可接受但欠佳,碘海醇GFR测定不充分;VAMS总体性能较差。
要点
- DBS他克莫司谷浓度P15=92.0%,AUC的P20=95.8%,方法一致性优良。
- DBS肌酐基GFR趋势监测P20=80%,达到预设接受阈值。
- DBS碘海醇GFR测定P20=75%,性能不充分;VAMS总体性能较差。
核心结论
- 该 assay 成功验证了DBS中他克莫司、MPA和肌酐的定量,可支持肾移植受者远程肾功能趋势监测与免疫抑制剂治疗药物监测。
研究设计与样本
- 研究开发液相色谱-串联质谱法,在DBS和VAMS中定量他克莫司、MPA、肌酐和碘海醇。
- 临床验证直接比较25例肾移植受者的配对DBS、VAMS与静脉参考样本。
- 患者于免疫抑制剂摄入前5-15分钟给予碘海醇,并在其后0、1、2、3小时采样,估算他克莫司与MPA的AUC及肌酐基与碘海醇基GFR。
- 方法一致性采用Passing-Bablok回归、Bland-Altman分析及参考值15-30%范围内百分比(P15-P30)评估,P20接受阈值为80%。
主要发现
- DBS他克莫司谷浓度方法一致性优良(n=25,P15=92.0%)。
- DBS他克莫司AUC方法一致性优良(n=25,P20=95.8%)。
- DBS肌酐基GFR趋势监测方法一致性 adequate(n=25,P20=80%)。
- DBS MPA AUC方法一致性 suboptimal(n=16,P20=68.8%),但P30为100%故认为可接受。
- DBS碘海醇GFR测定性能不充分(n=24,P20=75%);VAMS总体性能较差,特定情形可考虑。
关键数值与推荐
- P20接受阈值为80%。
- DBS他克莫司谷浓度P15=92.0%(n=25)。
- DBS他克莫司AUC P20=95.8%(n=25)。
- DBS肌酐基GFR趋势监测P20=80%(n=25)。
- DBS MPA AUC P20=68.8%(n=16),P30=100%;DBS碘海醇GFR P20=75%(n=24)。
临床怎么用
- 可采用DBS远程监测他克莫司谷浓度与AUC,以及肌酐基GFR趋势。
- DBS MPA AUC可接受但欠佳,解读时需谨慎。
- 不宜采用DBS碘海醇GFR测定;VAMS仅在特定情形考虑。
局限性
- 临床验证样本量有限(配对样本来自25例肾移植受者,部分分析n=16或24)。
- DBS MPA AUC与碘海醇GFR测定方法一致性未达预设P20阈值。
- VAMS总体性能较差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Immunosuppressant and kidney function monitoring are crucial for kidney transplant recipient follow-up. Microsamples enable remote sampling and minimise patient burden as compared to conventional venous sampling at the clinic. We developed a liquid chromatography-tandem mass spectrometry assay to quantify tacrolimus, mycophenolic acid (MPA), creatinine and iohexol in dried blood spot (DBS), and volumetric absorptive microsample (VAMS) samples. METHODS: The assay was successfully validated analytically for all analytes. Clinical validation was conducted by direct comparison of paired DBS, VAMS and venous reference samples from 25 kidney transplant recipients. Patients received iohexol 5-15 minutes before immunosuppressant intake and were sampled 0, 1, 2 and 3 hours thereafter, enabling tacrolimus and MPA area under the concentration-time curve (AUC) and creatinine-based and iohexol-based glomerular filtration rate (GFR) estimation. Method agreement was evaluated using Passing-Bablok regression, Bland-Altman analysis and the percentages of values within 15-30% of the reference (P15 -P30 ) with a P20 acceptance threshold of 80%. RESULTS: For DBS samples, method agreement was excellent for tacrolimus trough concentrations (n = 25, P15 = 92.0%) and AUCs (n = 25; P20 = 95.8%) and adequate for creatinine-based GFR trend monitoring (n = 25; P20 = 80%). DBS-based MPA AUC assessment showed suboptimal agreement (n = 16; P20 = 68.8%), but was considered acceptable given its P30 of 100%. The assay performed inadequately for DBS-based iohexol GFR determination (n = 24; P20 = 75%). The VAMS technique generally showed inferior performance, but can be considered for certain situations. CONCLUSION: The assay was successfully validated for tacrolimus, MPA and creatinine quantification in DBS samples, enabling simultaneous remote kidney function trend monitoring and immunosuppressant therapeutic drug monitoring in kidney transplant recipients.
引用
- Zwart TC, Metscher E, van der Boog PJM, et al. Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients. Br J Clin Pharmacol. 2022. PMID: 35670960. doi:10.1111/bcp.15433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。